Risk factors for heart attack, stroke, and venous thrombosis associated with hormonal contraceptive use

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 4, 2011, Pages 323-331

  Zakharova, Marina Y ^a   Meyer, Rachel M ^a   Brandy, Kyle R ^a   Datta, Yvonne H ^b   Joseph, Marilyn S ^a   Schreiner, Pamela J ^a   Rao, Gundu H ^b   Divani, Afshin A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

birth control; blood clot; heart attack; hormonal contraceptive; stroke; venous thrombus

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CHOLESTEROL; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; FIBRINOGEN; GESTAGEN; GESTODENE; GLUCOSE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; NORGESTIMATE; PROGESTERONE; PROTEIN S; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BIRTH CONTROL; BRAIN ISCHEMIA; CELL INTERACTION; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; ENDOTHELIUM CELL; FOLLOW UP; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MACROPHAGE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW (TOPIC); T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; VEIN THROMBOSIS;

CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE; VENOUS THROMBOSIS;

EID: 80052695353     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610368670     Document Type: Review

References (76)

1. Bengtsson LP [Fertility control in man: the history of contraception from antiquity to the present]. Lakartidningen. 1977 ; 74 (51). 4598-4600. (Pubitemid 8247582)
2. Connell EB Contraception in the prepill era. Contraception. 1999 ; 59 (1 Suppl). 7S - 10S. (Pubitemid 29174402)
3. Youssef H. The history of the condom. J R Soc Med. 1993 ; 86 (4). 226-228. (Pubitemid 23103686)
4. Kramer TH, Mosely JA, Rivera A., Ottomanelli G., Li PW, Bihari B. Condom knowledge, history of use, and attitudes among chemically addicted populations. J Subst Abuse Treat. 1991 ; 8 (4). 241-246.
5. Goldzieher JW Estrogens in oral contraceptives: historical perspectives. Johns Hopkins Med J. 1982 ; 150 (5). 165-169. (Pubitemid 12121956)
6. Goldzieher JW The history of steroidal contraceptive development: the estrogens. Perspect Biol Med. 1993 ; 36 (3). 363-368. (Pubitemid 23131456)
7. Fraser IS Forty years of combined oral contraception: the evolution of a revolution. Med J Aust. 2000 ; 173 (10). 541-544.
8. Diczfalusy E. Gregory pincus and steroidal contraception: a new departure in the history of mankind. J Steroid Biochem. 1979 ; 11 (1A). 3-11. (Pubitemid 9234941)
9. Belaisch J., Hommais-loufrani B. [Oral contraception: evolution of concepts over the last thirty years]. Contracept Fertil Sex (Paris). 1987 ; 15 (11 Suppl). 1-8.
10. Amy JJ, Tripathi V. Contraception for women: An evidence based overview. BMJ. 2009 ; 339: b2895.
11. Ladipo OA, Akinso SA Contraceptive implants. Afr J Reprod Health. 2005 ; 9: 16-23.
12. Roell A., Schueller P., Schultz A., et al. Effect of oral contraceptives and ovarian cycle on platelet function. Platelets. 2007 ; 18 (2). 165-170. (Pubitemid 46398999)
13. Sandset PM, Hoibraaten E., Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thromb Res. 2009 ; 123 (Suppl 2). S70 - S73.
14. Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 1996 ; 103 (3). 261-267. (Pubitemid 26075461)
15. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002 ; 22 (2). 201-210. (Pubitemid 34127028)
16. Rosing J., Curvers J., Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol. 2001 ; 95 (2). 193-197. (Pubitemid 32297717)
17. Rosing J., Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol. 1999 ; 180 (6pt2). S375 - S382.
18. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991 ; 133 (1). 32-37.
19. World health organization collaborative study of cardiovascular disease and steroid hormone contraception. Lancet. 1995 ; 346 (8990). 1582-1588.
20. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP Enhancement by factor v leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995 ; 346 (8990). 1593-1596. (Pubitemid 26001841)
21. Kemmeren JM, Algra A., Grobbee DE Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001 ; 323 (7305). 131-134. (Pubitemid 32678382)
22. van Hylckama Vlieg A., Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the mega case-control study. BMJ. 2009 ; 339: b2921.
23. Hellan M., Kuhnel E., Speiser W., Lechner K., Eichinger S. Familial lupus anticoagulant: A case report and review of the literature. Blood Coagul Fibrinolysis. 1998 ; 9 (2). 195-200. (Pubitemid 28216266)
24. Simioni P., Sanson BJ, Prandoni P., et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999 ; 81 (2). 198-202. (Pubitemid 29078302)
25. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y., Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost. 2005 ; 3 (6). 1213-1217. (Pubitemid 41725244)
26. Bertina RM, Koeleman BP, Koster T., et al. Mutation in blood coagulation factor v associated with resistance to activated protein C. Nature. 1994 ; 369 (6475). 64-67. (Pubitemid 24144355)
27. Olivieri O., Friso S., Manzato F., et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 1995 ; 91 (2). 465-470.
28. Rosing J., Middeldorp S., Curvers J., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet. 1999 ; 354 (9195). 2036-2040.
29. Kemmeren JM, Algra A., Meijers JCM, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor vleiden mutation: a randomized trial. Blood. 2004 ; 103 (3). 927-933. (Pubitemid 38129552)
30. Hassan A., Hunt BJ, O'Sullivan M., et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004 ; 127 (pt1). 212-219. (Pubitemid 38055360)
31. Cauci S., Di Santolo M., Culhane JF, Stel G., Gonano F., Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity c-reactive protein and homocysteine in young women. Obstet Gynecol. 2008 ; 111 (4). 857-864. (Pubitemid 351482617)
32. Pruissen DMO, Slooter AJC, Rosendaal FR, van der Graaf Y., Algra A. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood. 2008 ; 111 (3). 1282-1286. (Pubitemid 351213411)
33. Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., Sandset PM Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000 ; 84 (6). 961-967. (Pubitemid 32014029)
34. Scarabin PY, Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997 ; 17 (11). 3071-3078. (Pubitemid 28016061)
35. Norris LA, Bonnar J. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives. Thromb Haemost. 1994 ; 72 (6). 926-930.
36. Middeldorp S., Meijers JC, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000 ; 84 (1). 4-8. (Pubitemid 30433659)
37. Plu-Bureau G., Scarabin PY, Bara L., Malmejac A., Guize L., Samama M. Factor vii activation and oral contraceptives. Thromb Res. 1993 ; 70 (3). 275-280. (Pubitemid 23151335)
38. Scarabin PY, Plu-Bureau G., Zitoun D., Bara L., Guize L., Samama MM Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on pai-1 activity. Thromb Haemost. 1995 ; 74 (3). 928-932.
39. Walter B., Weiss C., Dorsch M., Bartsch P. Exercise-induced fibrin formation is enhanced in women using third-generation oral contraceptives. J Thromb Haemost. 2006 ; 4 (4). 898-899.
40. Schorer AE, Gerrard JM, White JG, Krivit W. Oral contraceptive use alters the balance of platelet prostaglandin and thromboxane synthesis. Prostaglandins Med. 1978 ; 1 (1). 5-11. (Pubitemid 9197102)
41. Feuring M., Christ M., Roell A., et al. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis. 2002 ; 13 (5). 443-447. (Pubitemid 35001861)
42. Johnson JV, Lowell J., Badger GJ, Rosing J., Tchaikovski S., Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol. 2008 ; 111 (2pt1). 278-284. (Pubitemid 351653416)
43. Cahill M., Mistry R., Chapman C., Wood JK, Barnett DB Effects of age, sex and the oral contraceptive on the platelet membrane fibrinogen binding site (glycoprotein IIb/IIIa). Br J Clin Pharmacol. 1992 ; 33 (1). 11-15.
44. Folsom AR, Qamhieh HT, Flack JM, et al. Plasma fibrinogen: levels and correlates in young adults. The coronary artery risk development in young adults (CARDIA) study. Am J Epidemiol. 1993 ; 138 (12). 1023-1036.
45. Norris LA, Devitt M., Bonnar J. The role of thromboxane a2 in increased whole blood platelet aggregation in oral contraceptive users. Thromb Res. 1996 ; 81 (4). 407-417. (Pubitemid 26100411)
46. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized shwartzman reaction. Blood. 1991 ; 78 (6). 1496-1502.
47. Dahm A., Rosendaal FR, Andersen TO, Sandset PM Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. Br J Haematol. 2006 ; 132 (3). 333-338. (Pubitemid 43381540)
48. van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost. 2008 ; 6 (2). 346-351.
49. Webber LS, Hunter SM, Baugh JG, Srinivasan SR, Sklov MC, Berenson GS The interaction of cigarette smoking, oral contraceptive use, and cardiovascular risk factor variables in children: the Bogalusa Heart Study. Am J Public Health. 1982 ; 72 (3). 266-274.
50. Kim C., Siscovick DS, Sidney S., Lewis CE, Kiefe CI, Koepsell TD Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA study. Coronary artery risk development in young adults. Diabetes Care. 2002 ; 25 (6). 1027-1032. (Pubitemid 41110489)
51. Feinberg MW, Watanabe M., Lebedeva MA, et al. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem. 2004 ; 279 (16). 16388-16393. (Pubitemid 38509335)
52. Buchbinder S., Kratzsch J., Fiedler GM, et al. Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest. 2008 ; 68 (2). 140-144. (Pubitemid 351481731)
53. Vitale C., Cornoldi A., Gebara O., et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause. 2005 ; 12 (5). 552-558. (Pubitemid 41362079)
54. Verma S., Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between c-reactive protein and cardiovascular disease. Circulation. 2004 ; 109 (17). 2058-2067. (Pubitemid 38620212)
55. van Rooijen M., Hansson LO, Frostegard J., Silveira A., Hamsten A., Bremme K. Treatment with combined oral contraceptives induces a rise in serum c-reactive protein in the absence of a general inflammatory response. J Thromb Haemost. 2006 ; 4 (1). 77-82.
56. Silvestri A., Gebara O., Vitale C., et al. Increased levels of c-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation. 2003 ; 107 (25). 3165-3169. (Pubitemid 36793086)
57. Kluft C., Leuven JA, Helmerhorst FM, Krans HM Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2002 ; 39 (3). 149-154. (Pubitemid 36398240)
58. Friedman GD, Tekawa I., Grimm RH, Manolio T., Shannon SG, Sidney S. The leucocyte count: Correlates and relationship to coronary risk factors: the CARDIA study. Int J Epidemiol. 1990 ; 19 (4). 889-893.
59. Morin-Papunen L., Martikainen H., McCarthy MI, et al. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am J Obstet Gynecol. 2008 ; 199 (5). 529.e1-529.10.
60. Boyce J., Fawcett JW, Noall EW Coronary thrombosis and conovide. Lancet. 1963 ; 1 (7272). 111.
61. Inman WH, Vessey MP Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J. 1968 ; 2 (5599). 193-199.
62. Oral contraception and increased risk of cerebral ischemia or thrombosis. Collaborative group for the study of stroke in young women. N Engl J Med. 1973 ; 288 (17). 871-878.
63. Margolis KL, Adami HO, Luo J., Ye W., Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril. 2007 ; 88 (2). 310-316. (Pubitemid 47212162)
64. Mant J., Painter R., Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol. 1998 ; 105 (8). 890-896. (Pubitemid 28423506)
65. Curtis KM, Mohllajee AP, Martins SL, Peterson HB Combined oral contraceptive use among women with hypertension: a systematic review. Contraception. 2006 ; 73 (2). 179-188. (Pubitemid 43087767)
66. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. [Commentary: Oral contraceptives and myocardial infarction: reassuring new findings]. BMJ. 1999 ; 318 (7198). 1579-1584. (Pubitemid 29267763)
67. Leblanc ES, Laws A. Benefits and risks of third-generation oral contraceptives. J Gen Intern Med. 1999 ; 14 (10). 625-632. (Pubitemid 29506148)
68. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1997 ; 349 (9060). 1202-1209.
69. Sidney S., Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation. 1998 ; 98 (11). 1058-1063. (Pubitemid 28420696)
70. Farley TM, Meirik O., Chang CL, Poulter NR Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 1998 ; 52 (12). 775-785. (Pubitemid 28523874)
71. Tanis BC, Bloemenkamp DG, van den Bosch MA, et al. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol. 2003 ; 122 (3). 471-478. (Pubitemid 36951633)
72. Tanis BC, van den Bosch Maaj, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001 ; 345 (25). 1787-1793.
73. Middeldorp S. Epidemiology of hormone-related venous thromboembolism. Thromb Res. 2009 ; 123 (suppl 2). S65 - S69.
74. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Lancet. 1995 ; 346 (8990). 1575-1582.
75. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M., MacRae KD Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational research group on oral contraceptives and the health of young women. BMJ. 1996 ; 312 (7023). 83-88.
76. Weiss C., Walter B., Dorsch MF, Bartsch P. Fibrinolytic response to exercise in women using third-generation oral contraceptives. Blood Coagul Fibrinolysis. 2006 ; 17 (7). 563-568. (Pubitemid 44434968)